Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

EXPECTED DECREASE IN NET LOSS

This announcement is made by China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board ("**Board**") of directors ("**Directors**") of the Company wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the information currently available:

(i) the Board expects to record a significant increase in revenue by approximately 25% for the six months ended 30 June 2021 as compared to the revenue for the six months ended 30 June 2020; and

(ii) the Board expects to record a significant decrease in net loss by approximately 80% for the six months ended 30 June 2021 as compared to the net loss for the six months ended 30 June 2020.

The increase in revenue for the six months ended 30 June 2021 was primarily due to the increase in demand from the recovery of the market during the period.

The decrease in net loss for the six months ended 30 June 2021 was primarily due to the increase in gross profit and gain on disposal of a subsidiary during the period.

The information contained in this announcement is based on the preliminary assessment of the information currently available to the Board and not on any figures or information which have been reviewed by the Company's audit committee. The unaudited consolidated interim results of the Group may be subject to adjustments following further review by the Company's audit committee and the Board. The Group's interim results for the six months ended 30 June 2021 are expected to be announced by 31 August 2021 in compliance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 27 August 2021

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Mr. Pan Fei and Dr. Zhao Yubiao.